Year None 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 Sep 14, 2026 Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy Sep 03, 2026 Tenaya Therapeutics to Participate in Upcoming September Investor Conferences Aug 05, 2026 Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Aug 04, 2026 Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference Jul 14, 2026 Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Jun 29, 2026 Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer Jun 03, 2026 Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms Jun 02, 2026 Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026 May 29, 2026 Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026 May 15, 2026 Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 17
Sep 14, 2026 Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
Aug 05, 2026 Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 04, 2026 Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
Jun 03, 2026 Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms
Jun 02, 2026 Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026
May 15, 2026 Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC
